Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
2.000
+0.160 (8.70%)
At close: Dec 20, 2024, 4:00 PM
1.950
-0.050 (-2.50%)
After-hours: Dec 20, 2024, 5:51 PM EST
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
68
Market Cap
62.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | 2.31M | 391.83K | 20.41% |
| Dec 31, 2019 | 1.92M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CareCloud | 111.01M |
| Atara Biotherapeutics | 100.44M |
| Repare Therapeutics | 66.52M |
| Scilex Holding Company | 50.83M |
| Aadi Bioscience | 25.07M |
| BioAtla | 11.00M |
| Kronos Bio | 9.86M |
| Dyadic International | 3.36M |
IMRX News
- 3 days ago - Immuneering Launches Pancreatic Cancer Advisory Board - GlobeNewsWire
- 8 days ago - Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? - Benzinga
- 10 days ago - Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma - GlobeNewsWire
- 25 days ago - Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - GlobeNewsWire
- 4 months ago - Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 months ago - Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer - GlobeNewsWire